{
    "organizations": [],
    "uuid": "c0cb9e4b9cd5c87d2a4dd53347ec7269afb6fff2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rocket-pharmaceuticals-presents-up/brief-rocket-pharmaceuticals-presents-updated-data-from-phase-1-2-gene-therapy-trial-of-rp-l102-idUSASC0A2YH",
    "ord_in_thread": 0,
    "title": "BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 18 (Reuters) - Rocket Pharmaceuticals Inc:\n* ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING\n* ROCKET PHARMACEUTICALS - CONTINUED CLINICAL EVIDENCE DEMONSTRATES RP-L102 CAN RESTORE BONE MARROW FUNCTION OF FANCONI ANEMIA PATIENTS WITHOUT CONDITIONING\n* ROCKET PHARMACEUTICALS INC - ALL PATIENTS DEMONSTRATED CONTINUED IMPROVEMENT IN ENGRAFTMENT FOLLOWING ADMINISTRATION OF RP-L102 IN TRIAL\n* ROCKET PHARMACEUTICALS INC - NO SERIOUS DRUG-RELATED ADVERSE EVENTS HAVE BEEN OBSERVED TO DATE IN TRIAL\n* ROCKET PHARMACEUTICALS INC - ADDITIONAL PATIENT DATA FROM FA PROGRAM IS EXPECTED OVER NEXT 12-18 MONTHS\n* ROCKET PHARMACEUTICALS - ROCKET WILL ENGAGE WITH REGULATORY AUTHORITIES TO PROGRESS RP-L102 TOWARDS A POTENTIAL GLOBAL REGISTRATIONAL STUDY IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-19T04:22:00.000+03:00",
    "crawled": "2018-05-19T15:36:13.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "rocket",
        "pharmaceutical",
        "inc",
        "rocket",
        "pharmaceutical",
        "present",
        "updated",
        "data",
        "phase",
        "gene",
        "therapy",
        "trial",
        "patient",
        "fanconi",
        "anemia",
        "american",
        "society",
        "gene",
        "cell",
        "therapy",
        "asgct",
        "annual",
        "meeting",
        "rocket",
        "pharmaceutical",
        "continued",
        "clinical",
        "evidence",
        "demonstrates",
        "restore",
        "bone",
        "marrow",
        "function",
        "fanconi",
        "anemia",
        "patient",
        "without",
        "conditioning",
        "rocket",
        "pharmaceutical",
        "inc",
        "patient",
        "demonstrated",
        "continued",
        "improvement",
        "engraftment",
        "following",
        "administration",
        "trial",
        "rocket",
        "pharmaceutical",
        "inc",
        "serious",
        "adverse",
        "event",
        "observed",
        "date",
        "trial",
        "rocket",
        "pharmaceutical",
        "inc",
        "additional",
        "patient",
        "data",
        "fa",
        "program",
        "expected",
        "next",
        "month",
        "rocket",
        "pharmaceutical",
        "rocket",
        "engage",
        "regulatory",
        "authority",
        "progress",
        "towards",
        "potential",
        "global",
        "registrational",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}